FDA And EU Regulators Find Data Integrity Lapses Are Still A Major GMP Problem
Executive Summary
The large number of US FDA warning letters going to firms for data integrity failings is mirroring trends with EU regulatory authorities, who are flagging data integrity failings in almost half of their GMP non-compliance reports. The issue strikes close to home for one FDA official.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.